Investors Urged to Act as MoonLake Faces Lawsuit After Massive Stock Drop and Nanobody Controversy
On December 15, 2025, a critical deadline looms for investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) as a class action lawsuit progresses, led by the renowned plaintiffs' rights firm Hagens Berman. This lawsuit comes on the heels of alarming news—MoonLake's stock has plummeted almost 90%, a staggering drop from $61.99 to just $6.24, following disappointing Phase 3 trial results for its chief drug candidate, sonelokimab (SLK).
Hagens Berman has sounded the alarm, urging those who have suffered substantial losses due to this stock decline to act quickly and submit their claims. The lawsuit highlights serious allegations that the company misled investors regarding the clinical benefits of its innovative Nanobody technology. The firm points out that MoonLake consistently asserted the superiority of its Nanobody structure over traditional monoclonal antibodies, particularly in relation to BIMZELX, an FDA-approved competitor.
Reed Kathrein, a partner at Hagens Berman, explained: "The fundamental issue lies in the promises made by MoonLake regarding the efficacy of their Nanobody treatment. When the negative results from the VELA-2 trial surfaced, those assurances collapsed, leading to substantial financial losses for investors." The trial’s failure to meet its primary endpoint raised serious doubts about the drug's effectiveness, and investors were left reeling from this unexpected downturn.
The timeline of this controversy stretches back to the class period, which spans from March 10, 2024, to September 29, 2025. Following the stock crash on September 29, the market reacted swiftly to the news of the trial's failure, putting more scrutiny on MoonLake’s claims. Investors who acquired stocks during this period are particularly encouraged to contact Hagens Berman to explore their legal avenues.
Stakeholders in MoonLake are faced with choices that could significantly affect their financial standings. To that end, Hagens Berman has made it clear they are prepared to assist investors in navigating this turbulence, ensuring that those affected by the stock's plummet understand their rights and options. Interested investors must act promptly as legal proceedings are already underway, and deadlines for representation are rapidly approaching.
This case also opens doors for whistleblowers with more direct information about MoonLake’s internal practices to contribute to this investigation, potentially qualifying for protections and rewards under the SEC's whistleblower program. By submitting original information, those with knowledge might receive up to 30% of any recovery achieved by the SEC.
As the deadline of December 15 inches closer, MoonLake investors are reminded not to delay in reaching out to legal experts well-versed in securities law. The ramifications of this lawsuit could be extensive, impacting investor sentiment and corporate accountability going forward. More details on how to file a claim can be found through Hagens Berman’s online resources, and interested parties are encouraged to return to the firm's website for updates on this developing situation. Following Hagens Berman's updates through their social media will also keep individuals informed on pertinent changes.
MoonLake’s future hangs in the balance as litigation unfolds, and it serves as a crucial reminder that in the world of biotech investments, due diligence and a keen awareness of market dynamics are essential. As the Class Actions materialize, both the company and investors will be kept in the spotlight, illustrating the continued interface between scientific promise and economic reality.
Hagens Berman has sounded the alarm, urging those who have suffered substantial losses due to this stock decline to act quickly and submit their claims. The lawsuit highlights serious allegations that the company misled investors regarding the clinical benefits of its innovative Nanobody technology. The firm points out that MoonLake consistently asserted the superiority of its Nanobody structure over traditional monoclonal antibodies, particularly in relation to BIMZELX, an FDA-approved competitor.
Reed Kathrein, a partner at Hagens Berman, explained: "The fundamental issue lies in the promises made by MoonLake regarding the efficacy of their Nanobody treatment. When the negative results from the VELA-2 trial surfaced, those assurances collapsed, leading to substantial financial losses for investors." The trial’s failure to meet its primary endpoint raised serious doubts about the drug's effectiveness, and investors were left reeling from this unexpected downturn.
The timeline of this controversy stretches back to the class period, which spans from March 10, 2024, to September 29, 2025. Following the stock crash on September 29, the market reacted swiftly to the news of the trial's failure, putting more scrutiny on MoonLake’s claims. Investors who acquired stocks during this period are particularly encouraged to contact Hagens Berman to explore their legal avenues.
Stakeholders in MoonLake are faced with choices that could significantly affect their financial standings. To that end, Hagens Berman has made it clear they are prepared to assist investors in navigating this turbulence, ensuring that those affected by the stock's plummet understand their rights and options. Interested investors must act promptly as legal proceedings are already underway, and deadlines for representation are rapidly approaching.
This case also opens doors for whistleblowers with more direct information about MoonLake’s internal practices to contribute to this investigation, potentially qualifying for protections and rewards under the SEC's whistleblower program. By submitting original information, those with knowledge might receive up to 30% of any recovery achieved by the SEC.
As the deadline of December 15 inches closer, MoonLake investors are reminded not to delay in reaching out to legal experts well-versed in securities law. The ramifications of this lawsuit could be extensive, impacting investor sentiment and corporate accountability going forward. More details on how to file a claim can be found through Hagens Berman’s online resources, and interested parties are encouraged to return to the firm's website for updates on this developing situation. Following Hagens Berman's updates through their social media will also keep individuals informed on pertinent changes.
MoonLake’s future hangs in the balance as litigation unfolds, and it serves as a crucial reminder that in the world of biotech investments, due diligence and a keen awareness of market dynamics are essential. As the Class Actions materialize, both the company and investors will be kept in the spotlight, illustrating the continued interface between scientific promise and economic reality.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.